ESMO 2016 | Niraparib as maintenance for platinum-sensitive ovarian cancer – results from ENGOT-OV16/NOVA trial
Sven Mahner, MD, PhD of the University Medical Center Hamburg-Eppendorf Hamburg, Germany talks about the Phase III trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial, NCT01847274). Dr Mahner explains that ovarian cancer is a common disease, which in the first-line setting, needs extensive surgery and chemotherapy. However, the majority of patients recur and they are re-treated with chemotherapy. The trial looked at maintenance therapy with niraparib after recurrent chemotherapy. According to Dr Mahner, they observed a large benefit for patients receiving niraparib maintenance in both, the germline BRCA (gBRCA) mutation and non-gBRCA mutated patient populations.
Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
Get great new content delivered to your inboxSign up